UPDATE: MiMedx Group (MDXG) Reports Q3 EPS of $0.08, Offers Q4 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- AMD stock jumps as chip rally builds ahead of summit
MiMedx Announces Record Results For Third Quarter Of 2017 And Raises Full Year Revenue Guidance
October 26, 2017 2:00 PM EDTMARIETTA, Ga., Oct. 26, 2017 /PRNewswire/ --Â MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its record results for the third quarter of 2017.
Third Quarter 2017 Financial HighlightsÂ
Q3 2017 revenue of $84.6 million exceeded MiMedx guidance range of $79 to $80 million Q3 2017 revenue grew 31% over Q3 2016 revenue Wound Care revenue of $61.9 million grew 24% over Q3 2016 Surgical, Sports... More